Occupational Activity – Page 32

23andMe Stock Surges as CEO Considers Taking Company Private

1 year ago talkbio0Tagged CEO, Privatization Plans, Science of genetics, Stock Jump

23andMe, Stock Jump, CEO, Privatization Plans, Genetics Company

Arrowhead’s Plozasiran Projected to Surpass $700M in Sales by 2032, Addressing Major Unmet Needs in Dyslipidemia Treatment

1 year ago talkbio0Tagged 2032, APOC3 gene, Arrowhead, cellular targeting, Dyslipidemias, Familial chylomicronemia syndrome, FCS, Fetal Bovine Serum, GlobalData, Plozasiran, Projections and Predictions, Sales - occupational activity, SHTG, Triglycerides, Unmet Needs

Arrowhead Pharmaceuticals, Plozasiran, Dyslipidemia, GlobalData, Sales Forecast, $700M, 2032, Unmet Needs, Triglyceride Reduction, APOC3 Targeting, SHTG (Severe Hypertriglyceridemia), FCS (Familial Chylomicronemia Syndrome), Mixed Dyslipidemia

Boehringer Ingelheim Leverages Late-Stage Pipeline for 25 New Launches over the Next Decade

1 year ago talkbio0Tagged Administration occupational activities, approvals, boehringer ingelheim, Decade, expansion, Heart failure, Jardiance, late-stage pipeline, launches, pipeline, reshuffle

Boehringer Ingelheim, Late-stage pipeline, 25 new launches, Decade, Jardiance, Heart failure approvals, Ofev, Pipeline expansion, Management reshuffle

Optimizing Pharmaceutical Supply Chains: The Evolving Role of Third-Party Logistics Providers

1 year ago talkbio0Tagged Administration occupational activities, Cold Chain Management, Pharma, Pharmaceutical Supply Chain, Regulatory Compliance, requirements, third-party logistics

Third-Party Logistics (3PL) Providers, Pharmaceutical Supply Chain, Pharma 4.0, Regulatory Compliance, Cold Chain Management, Data Mining and Management, Licensing Requirements

Medicare Partially Covers Weight Loss Drugs Amidst High Price Concerns and Future Negotiation Prospects

1 year ago talkbio0Tagged accessibility, Administration occupational activities, Affordability, Increased, Mediation, Medicare, Obesity drugs, premium, Prices, semaglutide, utilization qualifier, Wegovy

Medicare, Obesity drugs, Wegovy, Semaglutide, Price negotiation, Affordability, Accessibility, Premium increases, Utilization management

Clasp Therapeutics Launches with $150M Series A Funding to Develop Next-Generation T Cell Engaging Immunotherapies

1 year ago talkbio0Tagged Ataxia Telangiectasia Mutated Proteins, Catalio Capital Management, cellular targeting, CEO, CLASRP gene, engagers, financing characteristics, HLA Molecule Profiling, Holdings, Personalized Off-the-Shelf Therapies, Robert Ross, T-Lymphocyte, Third Rock

Clasp Therapeutics, $150M Series A Financing, T Cell Engagers, Personalized Off-the-Shelf Therapies, Targeting Mutated Protein Fragments, HLA Molecule Profiling, Novo Holdings/ Third Rock Ventures/ Catalio Capital Management, CEO Robert Ross